The primary analysis from FAKTION in 2020, was the first to report randomised data on the safety and efficacy of adding an AKT inhibitor to endocrine therapy for patients with advanced aromatase inhibitor-resistant ER-positive, HER2-negative breast cancer. This evidence concerns the gene CYP19A1 and breast cancer.